Dermatology
Psoriasis — Severity Assessment and Step-Up Therapy
PASI/DLQI-based severity classification and topical to biologic treatment escalation for plaque psoriasis
Source: NICE NG153 2019 / BAD
Step 1 of ~10
info
Psoriasis Assessment
Most common type: chronic plaque psoriasis (85–90%). Assess with PASI (Psoriasis Area and Severity Index) and DLQI (Dermatology Life Quality Index). Mild: PASI <10 + DLQI ≤10. Moderate-severe: PASI ≥10 or DLQI >10.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Dapsone · Anti-inflammatory / Antimicrobial
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Calcipotriol / Betamethasone Dipropionate · Combination Topical — Psoriasis
- Tazarotene · Topical Retinoid — Psoriasis / Acne
- Coal tar with calamine · Topical psoriasis preparation
- Coal tar with dithranol and salicylic acid · Topical psoriasis preparation
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
- Non-Melanoma Skin Cancer — BCC and SCC · NICE NG12 2015 / BAD NMSC Guidelines
Decision support only. Always apply local guidelines and clinical judgement.